Effects of Initiating Carvedilol in Patients With Severe Chronic Heart Failure
JAMAPublished 12 February 2003Open access
Henry Krum, Ellen B. Roecker, Paul Mohaçsi, Jean L. Rouleau, Michał Tendera, Andrew J.S. Coats
Citations307
SJR quartileQ1
SJR score5.35
SNIP10.71
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
Abstract
These data suggest that, in clinically euvolemic patients, the relation of benefit to risk during initiation of treatment with carvedilol is similar to that seen during long-term therapy with the drug. Our findings should provide the reassurance needed to encourage the high levels of use that are warranted by the results of long-term clinical trials.
Keywords
Medicine
Springer series in statisticsNonparametric Estimation from Incomplete Observations
45,533 Citations1992Edward L. Kaplan, Paul Meier
Journal of the Royal Statistical Society Series B (Statistical Methodology)Regression Models and Life-Tables
39,259 Citations1972D. R. Cox
Journal of the American Statistical AssociationNonparametric Estimation from Incomplete Observations
39,052 Citations1958Edward L. Kaplan, Paul Meier
The LancetEffect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)
5,122 Citations1999
Metoprolol controlled release/extended release (CR/XL) once daily in addition to standard therapy improved survival and the drug was well tolerated.
The LancetThe Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
4,913 Citations1999Lechat, P, Brunhuber, Kw +280 more
Beta-blocker therapy had benefits for survival in stable heart-failure patients and should not be extrapolated to patients with severe class IV symptoms and recent instability because safety and efficacy has not been established in these patients.
New England Journal of MedicineThe Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
4,656 Citations1996Milton Packer, Michael R. Bristow +5 more
Carvedilol reduces the risk or death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor.
New England Journal of MedicinePlasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure
3,116 Citations1984Jay N. Cohn, T. Barry Levine +6 more
Measurements of Hemodynamics, plasma norepinephrine, and plasma renin activity in patients with moderate to severe congestive heart failure suggest that a single resting venous blood sample showing the plasma norenphrine concentration provides a better guide to prognosis than other commonly measured indexes of cardiac performance.
New England Journal of MedicineEffect of Carvedilol on Survival in Severe Chronic Heart Failure
3,074 Citations2001Milton Packer, Andrew J.S. Coats +12 more
Journal of the American College of CardiologyACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary
1,919 Citations2001Sharon A. Hunt, David W. Baker +22 more
ACC Current Journal ReviewEffect of carvedilol on survival in severe chronic heart failure
1,665 Citations2001Milton Packer, Andrew J.S. Coats +1 more
The previously reported benefits of carvedilol with regard to morbidity and mortality in patients with mild-to-moderate heart failure were also apparent in the patients with severe heart failure who were evaluated in this trial.
CirculationACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)
1,434 Citations2001Sharon A. Hunt, David W. Baker +22 more
JAMAEffects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart Failure
1,382 Citations2000Åke Hjalmarson, Sidney Goldstein +22 more
In this study of patients with symptomatic heartfailure, metoprolol CR/XL improved survival, reduced the need for hospitalizations due to worsening heart failure, improved NYHA functional class, and had beneficial effects on patient well-being.
CirculationCarvedilol Produces Dose-Related Improvements in Left Ventricular Function and Survival in Subjects With Chronic Heart Failure
1,306 Citations1996Michael R. Bristow, Edward M. Gilbert +10 more
In subjects with mild to moderate heart failure from systolic dysfunction, carvedilol produced dose-related improvements in LV function and dose- related reductions in mortality and hospitalization rate and was generally well tolerated.
New England Journal of MedicineA Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure
1,006 Citations2001The Beta-Blocker Evaluation of Survival Trial Investigators
CirculationCarvedilol Inhibits Clinical Progression in Patients With Mild Symptoms of Heart Failure
635 Citations1996Wilson S. Colucci, Milton Packer +12 more
Carvedilol, when added to standard therapy, including an ACE inhibitor, reduces clinical progression in patients who are only mildly symptomatic with well-compensated heart failure, and significantly improved several secondary end points.
CirculationDouble-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure
617 Citations1996Milton Packer, Wilson S. Colucci +17 more
These findings indicate that, in addition to its favorable effects on survival, carvedilol produces important clinical benefits in patients with moderate to severe heart failure treated with digoxin, diuretics, and an ACE inhibitor.
The LancetRandomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
585 Citations1997Australia/New Zealand Heart Failure Research Collaborative Group, -
There was an overall reduction in events resulting in death or hospital admission, and a year of treatment with carvedilol resulted in the avoidance of one such serious event among every 12–13 of these patients with chronic stable heart failure.
Journal of the American College of CardiologyTime course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade
535 Citations1995Shelley Hall, Carlos G. Cigarroa +4 more
Long-term therapy with metoprolol results in a reversal of maladaptive remodeling with reduction in left ventricular volumes, regression ofleft ventricular mass and improved ventricular geometry by 18 months.
CirculationLong-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol.
447 Citations1989Finn Waagstein, Kenneth Caidahl +3 more
Patients with dilated cardiomyopathy had a low number of ventricular beta-adrenergic receptors compared with healthy control subjects, but long-term treatment with metoprolol caused a moderate up-regulation, which may facilitate a more normal response to sympathetic stimulation.
The American Journal of CardiologyCan physicians always explain the results of clinical trials? a case study of amlodipine in heart failure
277 Citations1999Milton Packer, Alan B. Miller
The American Journal of MedicineImportance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure
214 Citations1963Thomas E. Gaffney, Eugene Braunwald
It is suggested that the adrenergic nervous system plays an important compensatory role in the circulatory adjustments of patients to congestive heart failure, and the need for caution in the use of highly effective antiadrenergic drugs in the treatment of patients with limited cardiac reserve is emphasized.
CirculationEffects of Metoprolol CR in Patients With Ischemic and Dilated Cardiomyopathy
183 Citations2000
When added to ACE inhibitors, angiotensin II receptor antagonists, or both, the use of metoprolol CR improves ventricular function, reduces activation of the renin-angiotens in systems, and results in fewer deaths.
CirculationSex Differences in Management and Outcome After Acute Myocardial Infarction in the 1990s
169 Citations2000Shmuel Gottlieb, David Harpaz +8 more
This prospective nationwide observational community-based study of consecutive AMI patients hospitalized in the CCUs in the mid 1990s indicates that women fare significantly worse than do men at 30 days but not thereafter at 1-year.
Annals of Internal MedicineThe Effect of Beta Adrenergic Blockade on Patterns of Urinary Sodium Excretion
125 Citations1966Stephen E. Epstein, EUGENE BRAUNWALD
CirculationHerpesvirus Infection Accelerates Atherosclerosis in the Apolipoprotein E–Deficient Mouse
106 Citations2000Dagmar Alber, Kenneth L. Powell +3 more
It is demonstrated that a gamma-herpesvirus can accelerate atherosclerosis in the apoE-/- mouse, which suggests that the virus may initiate endothelial injury, which is believed to be an early event in the development of Atherosclerosis.
The Medical Journal of AustraliaChronic heart failure in Australian general practice: The Cardiac Awareness Survey and Evaluation (CASE) Study
95 Citations2001Henry Krum, Andrew Tonkin +3 more
To investigate the frequency and general practitioner awareness of patients with chronic heart failure (CHF), and to evaluate a cardiac algorithm and document cardiac investigations performed in establishing this diagnosis.
CirculationTolerability of β-Blocker Initiation and Titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
92 Citations2002Stephen S. Gottlieb, Michael L. Fisher +5 more
When carefully titrated, metoprolol CR/XL can be given safely to the overwhelming majority of patients with stable mild to moderate heart failure, with minimal side effects or deterioration.
The American Journal of CardiologyEditorial
82 Citations1997Eric J. Eichhorn, Michael R. Bristow
An editorial examines which beta-blocking agents are best tolerated and why, and describes how best to initiate treatment with these agents.
The American Journal of MedicineCurrent role of beta-adrenergic blockers in the management of chronic heart failure
66 Citations2001Milton Packer
Benefits of beta blockers are seen in patients already receiving ACE inhibitors, suggesting that combined blockade of two neurohormonal systems (renin-angiotensin system and sympathetic nervous system) can produce additive effects.